TABLE 5.
Antiserum or serumb | ELISA endpoint titer
|
Spirochetes surviving antiserum treatmenta
|
||||
---|---|---|---|---|---|---|
Blood-phase spirochetes plus serum diluted:
|
Cultured spirochetes plus serum diluted:
|
|||||
DbpA IgG | OspA IgG | 1:50 | 1:250 | 1:50 | 1:250 | |
Unadsorbed | 1,024,000 | <100 | 3 | 5 | 0 | 0 |
H. influenzae PAL-adsorbed | 512,000 | NDc | 2 | 3.5 | 0 | 0 |
DbpA-adsorbed | 32,000 | ND | 95 | 120 | 97 | 94 |
Uninfected-mouse serum | <500 | ND | 128 | 112 | 104 | 104 |
0.1 ml of cultured B. burgdorferi B31 diluted to approximately 103/ml or 0.075 ml of plasma samples from spirochetemic C3H.SCID mice were incubated with antiserum at 33°C for 90 min and then plated on BSKII agarose for enumeration of viable spirochetes as CFU. Values are means of duplicate platings.
Antisera pooled from C3H mice at week 16 of B. burgdorferi B31 infection was used untreated or after adsorption with PAL or DbpA. Uninfected-mouse serum was pooled from naive, uninfected C3H mice.
ND, not done.